-
Presentation at CAR-TCR Summit Europe demonstrates scalability and reduction in media usage enabling lower cost to produce dose of autologous T cell therapy
-
Quantum Flex expands as few as 6 million T cells to over 2 billion in 8 days
LAKEWOOD, CO, Feb. 23, 2023 – Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, for the first time today shared data generated from its Quantum Flex Cell Expansion System at a major conference, demonstrating how its hollow-fiber perfusion technology accelerates T cell therapy development in a variety of bioreactors. In today’s presentation at CAR-TCR Summit Europe in London, Terumo BCT scientists detailed the outcome of multiple T cell expansion runs, with a 60-70% reduction in media usage and 8.7-9.6 population doublings over the course of 8 days.
In a small bioreactor with a cost-effective [VH1] profile, like those commonly used for process development of autologous CAR-T cell therapies, Quantum Flex expanded 6 million CD3+ T cells at seed to over 2 billion viable cells, in just 8 days. And in a standard bioreactor, the yield was even greater, expanding 30 million CD3+ T cells to up to 22 billion cells, in the same time. The expanded cells displayed an optimal phenotype, including subsets of memory T cells, with minimal exhaustion marker expression.1
In a separate experiment, Terumo BCT scientists showed that even with a reduced start from one million viable cells at seed, continuous perfusion feeding allowed Quantum Flex to expand the population beyond the 2 billion-cell threshold in 10 days, with 95% viability at harvest.[SD2] This lower seeding requirement may extend therapy availability to patients whose low cell counts would otherwise preclude them from treatment options.
One key to Quantum Flex’s efficiency is a design feature allowing for flexible media usage. Using bags with dual ports allows for recirculation of media, which enables cost savings compared with single-use media consumption. As the latest data reinforces, the approach is scalable from process development through commercial manufacturing across a range of cell and gene therapy products.
“This is an impressive first demonstration of Quantum Flex’s advancements over even the last generation Quantum technology, which has previously shown robust T cell expansion with generation of stem-like memory T cells2,” said Dalip Sethi, Director of Scientific Affairs at Terumo BCT. “It also highlights the ‘flex’ in Quantum Flex, revealing how adaptable the system can be for the highly variable patient starting materials. We look forward to sharing additional data on the platform later this year.”
To learn more, visit https://reach.terumo-bct.com/quantum-flex-2022.
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees worldwide believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.
Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 130 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.
We have global headquarters in Lakewood, Colorado, U.S.A., along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.
References
[1] “Elevate your T-cell manufacturing process.” RegMedNet 2022 Oct
[2] Cunningham AW, et al. Stem-like memory T cells are generated during hollow fiber perfusion-based expansion and enriched after cryopreservation in an automated modular cell therapy manufacturing process. Cytotherapy. 2022 Nov;24(11):1148-1157. doi: 10.1016/j.jcyt.2022.07.009. Epub 2022 Aug 26. PMID: 36031522.
Media Contacts
Terumo Blood and Cell Technologies
Christine Romero
+1.720.273.9595
Christine.Romero@terumobct.com
press@terumobct.com
Image Box Communications
Neil Hunter / Michelle Boxall
+44 (0)20 8943 4685
neil@ibcomms.agency /michelle@ibcomms.agency
